Please login to the form below

Not currently logged in

Almirall and CRG announce non-melanoma skin cancer research collaboration

The partners will jointly develop novel preclinical models to identify new treatments for NMSC


Almirall SA and biomedical research institute, the Centre for Genomic Regulation (CRG), have announced a collaboration aimed at developing and distinguishing novel preclinical models to identify new treatments for non-melanoma skin cancer (NMSC).

NMSC belongs to a group of cancers that develop in the upper layers of the skin. Non-melanoma specifies more common kinds of skin cancer from the less common kind known as melanoma.

The two most common types of NMSC are squamous cell carcinoma and basal cell carcinoma, representing 70% and 25% of NMSC cases, respectively. Squamous cell carcinoma starts in the cells lining the top of the epidermis, while basal cell carcinoma starts in the cells lining the bottom of the epidermis.

Through the new partnership, Almirall investigators and CRG’s team of researchers will merge their knowledge to inaugurate experimental models that allow identification, as well as validation of new therapeutic approaches and the evaluation of new drugs for these diseases.

CRG’s group leader, professor Luciano Di Croce, said: “NMSC is not an aggressive cancer, meaning it has been historically difficult to model this disease in the lab. However, important technological advances combined with multiple 'omics’ approaches allow now to create truly functional scientific models for this skin cancer.

“Thus, it is an exciting opportunity to collaborate with Almirall and make important advances in studying one of the most frequent types of cancer."

The research partnership arises after AlmirallShare – the company’s open innovation platform for discovering innovative therapies for skin diseases – made a call for proposals. Formed in 2017, AlmirallShare was created to make dermatological research collaborations easier and accelerate the development of skin condition treatments.

The collaboration between Almirall and CRG represents another milestone in this endeavour, the company said, and builds on the eight established partnerships based on models, targets and new therapies for dermatological disease, including hidradenitis suppurativa.

Almirall’s chief scientific officer, Karl Ziegelbauer, said: “This collaboration with CRG brings us closer to our noble purpose of delivering world-class solutions that make a difference in patients' lives.

"It also reaffirms the success of our open innovation platform AlmirallShare as a key tool for building strategic partnerships.”

Article by
Jen Brogan

25th May 2023

From: Research



Subscribe to our email news alerts


Add my company
Research Partnership

Research Partnership, an Inizio Advisory Company, is a world-leading custom and syndicated global insights partner for health and life science...

Latest intelligence

Archetypes: Rethinking go-to-market expectations to drive commercial success
In this white paper, our consultants analyze trends spanning global policy developments, rising inflation, and increasingly complex customer journeys, and reveal a new data-driven approach to archetyping that crystalizes the...
Tuberculosis – why it remains a major global public health challenge
Innovative collaboration is required to address the major public health challenges around TB and expedite drug development...
Whitepaper: Closing the gap with compelling healthcare communications
Want to learn how to close the distance between a person’s current health and their healthiest possible self?...